TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: A prospective study introducing azacytidine plus CHOP as an initial treatment for PTCL showed sustained remission in 75% of evaluable patients, with TET2 mutations significantly associated with complete response, improved progression-free survival, and overall survival [16].